Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Trisomy 3 is a specific genomic aberration of t(14;18) negative follicular lymphoma

Leukemia volume 21, pages 2549–2551 (2007)Cite this article

Follicular lymphoma (FL) is the most frequent indolent lymphoma, accounting for approximately 20–40% of all non-Hodgkin lymphomas.1 It constitutes a distinct lymphoma entity in the WHO classification of hematologic neoplasms and is characterized by the proliferation of CD10(+) follicular center B-cells and by a specific chromosomal translocation, t(14;18) (q32;q21), which is present in approximately 80% of all cases.1 However, approximately 15–20% FL are known to lack t(14;18).2, 3

Previously, Jardin et al. (2002) reported that FL without t(14;18) and with BCL6 rearrangement is a distinct subtype.4 Horsman et al. (2003) investigated the cytogenetic aberrations of t(14;18) negative FL and found that the cases showing chromosome 18 duplication and BCL2-protein expression may comprise a unique subgroup of FL.3 Recently, Guo et al. (2005) reported that the t(14;18) positive group is a single tumor entity, most of which is accounted for by grades 1 and 2, whereas t(14;18) negative-FL was found to consist of distinct subgroups, majority of which is accounted for by grades 3.5 These reports suggest that t(14;18) negative FL comprise distinct subtypes.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Nathwani BN, Harris NL, Weisenburger DD . Follicular lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds). Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyons, France, 2001, p162–p167.

    Google Scholar 

  2. Horsman DE, Okamoto I, Ludkovski O, Ludkovsky O, Le N, Harder L et al. Follicular lymphoma lacking the t(14;18)(q32;q21): identification of two disease subtypes. Br J Hematol 2003; 120: 424–433.

    Article  Google Scholar 

  3. Vaandrager JW, Schuuring E, Raap T, Philippo K, Kleiverda K, Kluin P . Interphase FISH detection of BCL2 rearrangement in follicular lymphoma using breakpoint-flanking probes. Genes Chromosomes Cancer 2000; 27: 85–94.

    Article  CAS  PubMed  Google Scholar 

  4. Jardin F, Gaulard P, Buchonnet G, Contentin N, Lepretre S, Lenain P et al. Follicular lymphoma without t(14;18) and with BCL-6 rearrangement: a lymphoma subtype with distinct pathological, molecular and clinical characteristics. Leukemia 2002; 16: 2309–2317.

    Article  CAS  PubMed  Google Scholar 

  5. Guo Y, Karube K, Kawano R, Yamaguchi T, Suzumiya J, Huang GS et al. Low-grade follicular lymphoma with t(14;18) presents a homogenous disease entity otherwise the rest comprises minor groups of heterogeneous disease entities with bcl2 amplification, bcl6 translocation or other gene aberrances. Leukemia 2005; 19: 1058–1063.

    Article  CAS  PubMed  Google Scholar 

  6. Tagawa H, Suguro M, Tsuzuki S, Matsuo K, Karnan S, Okamoto M et al. Comparison of genome profiles for identification of distinct subtype of diffuse large B-cell lymphoma. Blood 2005; 106: 1770–1777.

    Article  CAS  PubMed  Google Scholar 

  7. Karube K, Guo Y, Suzumiya J, Sugita Y, Nomura Y, Yamamoto K et al. CD10(−)MUM1(+) follicular lymphoma lacks BCL2 translocation and shows characteristic biological and clinical features. Blood 2007; 109: 3076–3079.

    CAS  PubMed  Google Scholar 

  8. Falini B, Fizzotti M, Pucciarini A, Bigera B, Marafiori T, Gambacorta M et al. A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood 2000; 95: 2082–2092.

    Google Scholar 

Download references

Acknowledgements

This work was supported in part by Grants-in-Aid from Trade and Industry (METI); from the Ministry of Health, Labor and Welfare; from the Ministry of Education, Culture, Sports, Science and Technology (MS); from the Grant-in-Aid B Japan Society for the Promotion of Science (MS); from the Foundation of Promotion of Cancer Research (MS); from the Princess Takamatsu Cancer Research Fund (MS); from the Project research foundation of Aichi Cancer Center (HT); from the Grant-in-Aid C from the Japan Society for the Promotion of Science (HT); from Mochida memorial foundation for medical and pharmaceutical research (HT) and from Charitable trust laboratory medicine foundation of Japan (HT). The outstanding technical assistance from Ms Hiroko Suzuki and Ms Yumiko Kasugai is very much appreciated. We also thank Dr Toshitada Takahashi, the chancellor of Aichi Cancer Center, for his overall support.

Author information

Authors and Affiliations

  1. Division of Molecular Medicine, Aichi Cancer Center Research Institute, Aichi, Japan

    H Tagawa & M Seto

  2. Department of Pathology, School of Medicine, Kurume University, Kurume, Japan

    K Karube, Y Guo & K Ohshima

  3. Department of Pathology, State Key Laboratory of Cancer Biology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shannxi, People's Republic of China

    Y Guo

  4. Departments of Pathology and Internal Medicine, School of Medicine, Fukuoka University, Fukuoka, Japan

    M Takeshita & M Kikuchi

  5. Department of Cell Therapy, Aichi Cancer Center Hospital, Aichi, Japan

    Y Morishima

  6. Department of Pathology, School of Medicine, Nagoya University, Nagoya, Japan

    S Nakamura

Authors
  1. H Tagawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K Karube
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Y Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Takeshita
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M Kikuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Y Morishima
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. K Ohshima
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M Seto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H Tagawa.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tagawa, H., Karube, K., Guo, Y. et al. Trisomy 3 is a specific genomic aberration of t(14;18) negative follicular lymphoma. Leukemia 21, 2549–2551 (2007). https://doi.org/10.1038/sj.leu.2404817

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2404817

This article is cited by

Search

Advanced search

Quick links